This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Shimamoto, K. Articles by Iimura, O. Search for Related Content PubMed PubMed Citation Articles by Shimamoto, K. Articles by Iimura, O. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information High Blood Pressure

Hypertension, Vol 14, 375-378, Copyright © 1989 by American Heart Association

ARTICLES

Mechanisms of suppression of renal kallikrein activity in low renin essential hypertension and renoparenchymal hypertension

K Shimamoto, A Masuda, T Ando, N Ura, M Nakagawa, Y Mori, H Nakagawa, T Sakakibara, H Ogata and O Iimura
Second Department of Internal Medicine, Sapporo Medical College, Japan.

The mechanism of suppression of renal kallikrein activity in low renin essential hypertensive and renoparenchymal hypertensive patients was investigated in this study. From Sephadex G-200 column chromatography studies, a single kallikrein peak was observed in both kallikrein radioimmunoassay and kininogenase activity in all samples from normal subjects, low renin essential hypertensive and renoparenchymal hypertensive patients, and in purified kallikrein solution. The enzyme- specific activity around the kallikrein peak in all urine samples from each group was significantly lower than that in purified kallikrein, and a significantly lower specific activity was found in both patient groups than was found in normal subjects. Moreover, it was also recognized that the specific activity of kallikrein decreased in all cases with the increase of the molecular weight of kallikrein, and this tendency was observed more obviously in the low renin essential hypertensive and renoparenchymal hypertensive patients than in the normal subjects. These results suggest the presence of a kallikrein- specific inhibitor with a low molecular weight in human urine, although the possibility of a variant form of kallikrein cannot be excluded.